If you liked this article you might like

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
Roche CEO Bullish on U.S. Drug Market
Roche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market
Roche Posts Solid 2016 Profit, 2017 Outlook; Dividend Falls Short